Results 191 to 200 of about 212,304 (319)

Clinical Outcome Assessments in Parkinson's Disease: A Scoping Review of Current Rating Scales and Future Needs

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Clinical outcome assessments (COAs) are essential for evaluating symptom severity, treatment response, and disease progression in Parkinson's disease (PD). As clinical knowledge evolves, it is necessary to revisit the recommendation status on the COAs to ensure their continued relevance and validity. Objectives To provide an updated
Evita Papathoma, Panagiota Tsitsi, Nirosen Vijiaratnam, Camila Aquino, Stephen R. Duma, Norbert Kovacs, Kigocha Lameck Okeng'o, Aparna Wagle Shukla, Roongroj Bhidayasiri, Tiago A. Mestre, Alvaro Sanchez Ferro, Alberto J. Espay, Michelle H.S. Tosin, Matej Skorvanek, Ioanna Markaki   +14 more
wiley   +1 more source

Horizon scanning and drug expenditure for rare diseases: three-year predictive model in Italy 2025-2027. [PDF]

Health Econ Rev
Marcellusi A, Cazzato D, Guarnotta G, Aiello A, Bonfanti M, Bitonti R, Guardigni M, Lucchetti C, Luccini F, Canonico PL, Jommi C.   +10 more
europepmc   +1 more source

Types of Pain in Multiple System Atrophy

Movement Disorders, EarlyView.
Abstract Background Pain affects up to 87% of people with multiple system atrophy (MSA), but it remains unclear which types of pain contribute most to the overall burden. Objective To estimate the frequency of different types of pain in MSA individuals.
Nicole Campese, Mubasher A. Qamar, Maria Alexandra Chiriac, Georg Göbel, Julia Wanschitz, Andreas Schlager, Bianca Caliò, Fabian Leys, Pam Bower, Laura Zamarian, Anette Schrag, Roy Freeman, Horacio Kaufmann, Roberta Granata, Stefan Kiechl, Werner Poewe, Klaus Seppi, Gregor Wenning, K. Ray Chaudhuri, Alessandra Fanciulli   +19 more
wiley   +1 more source

Correction: Investigation of the impact of brewing parameters on toxic element and rare earth element contamination in oolong tea. [PDF]

Front Nutr
Wu S, Peng Z, Ou Y, Mhungu F, Wang Y, Zhang Y, Liu L, Lei J, Huang L, Peng R, Bai Z, Zhang W.   +11 more
europepmc   +1 more source

THE IMPACT OF IMPLEMENTING ENVIRONMENTAL MANAGEMENT SYSTEMS ON THE ECONOMICS OF THE PHARMACEUTICAL INDUSTRY- APPLIED STUDY

Walid Hamed Mosallam, Walid Hamed Saber Mosallam حامد Mosallam, Wael F. Abdel Basset, Madiha H. M. El-Sayed   +3 more
openalex   +1 more source

Showcasing Pharmaceutical Economics, Outcomes, and Health Policy: An Update in Clinical Therapeutics [PDF]

, 2013
Denys T. Lau
openalex   +1 more source

Reconsidering Volume‐Based Drug Procurement Policy: The Consequences of Manufacturers' Optimal Production Planning and Breach Strategies

Naval Research Logistics (NRL), EarlyView.
ABSTRACT This paper examines the impacts of Volume‐Based Procurement (VBP) policies on pharmaceutical supply chains, with a focus on the strategic behaviors of manufacturers. VBP aims to reduce costs and stabilize supplies by centralizing procurement through competition based on volumes and prices.
Nani Zhou, Tong Wang, Guohua Wan
wiley   +1 more source

Cost-effectiveness of hypofractionated radiation therapy versus conventional radiation therapy for unresectable stage III non-small cell lung cancer. [PDF]

Sci Rep
Zhang H, Liu Y, Zeng G, Hu S, Li H, Wang H.   +5 more
europepmc   +1 more source

Pharmaceutical Patents and Economic Inequality.

Health and human rights, 2023
openaire   +2 more sources

PHP1: THE ECONOMICS OF PARALLEL TRADE IN PHARMACEUTICALS: EXPERIENCES FROM SWEDEN

, 2001
U. Persson, Anders Anell
openalex   +1 more source